Preladenant is a potent (Ki = 1.1nM) and selective (>1000-fold over other adenosine receptors) adenosine A2A antagonist.1 It has shown efficacy in rodent and primate models of Parkinsons disease without inducing dyskinesias and displays antidepressant effects.1-3 It has been shown that activation of the adenosine A2A receptor blocks the activation of immune cells and increases the number of regulatory T-cells.4-6 Currently in clinical trials as combination therapy with pembrolizumab.7
* VAT and and shipping costs not included. Errors and price changes excepted
